A Phase II Study of Cabozantinib Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 09 Jul 2019
Price : $35 *
At a glance
- Drugs Cabozantinib (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer; Brain metastases
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 29 Aug 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Nov 2018.
- 29 Aug 2018 Status changed from recruiting to active, no longer recruiting.